CINSARC : Complexity INdex in SARComas

Applications

• Around 30,000 new cases of sarcomas are diagnosed every year in the US and EU
• Sarcomas are rare cancers for which treatments and prognoses can vary widely
• The classification and prediction of the metastasis risk is particularly difficult and currently the analysis is based on a histological grade.
• Such analysis is not very accurate and can often leads to sub-optimal patient management

Description

• A molecular signature (67 genes) was identified by a multidisciplinary team of researchers in Bordeaux and published in Nature Medicine in 2010.
• This signature, called CINSARC (Complexity INdex in SARComas), allows the classification of patients into 2 subgroups of good or poor prognosis depending on the metastasis risk.
• Applicable for NGS and CGH-array analysis of frozen and FFPE tumor material
• Efficacy retrospectively validated in the majority of sarcomas through tumor samples

Bénéfits

• CINSARC is more predictive than the histological grading
• CINSARC is the future gold standard in sarcoma medical practice

Maturation

The maturation with Aquitaine Science Transfert led to the validation of the CINSARC signature predictive value